Biotech firm abandons traditional treasury playbook in favor of cryptocurrencies.
A cancer drug developer has rocked Wall Street by implementing what is perhaps the most audacious crypto treasury strategy we have seen from a traditional biotech firm.
MAIA Biotechnology (NYSE American: MAIA) announced on October 7 that its Board of… [2146 chars]
Source: The Street | Published: 2025-10-07T16:13:11Z
Credit: The Street
